How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

404 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Large clonal outbreak of multidrug-resistant CC17 ST17 Enterococcus faecium containing Tn5382 in a Spanish hospital. (PubMed)

). Genes encoding antibiotic resistance (ampicillin, aminoglycosides, macrolides, quinupristin/dalfopristin, quinolones, tetracycline) and putative virulence traits were analysed.All isolates showed highly similar PFGE profiles and were assigned to the type MT1 by MLVA and to ST17 (CC17) by MLST. The Tn5382 type identified in all isolates was linked to pbp5 and contained a 5 bp deletion and 10 point mutations within the intergenic vanS(B)-vanY(B) region. Other resistance genes identified were erm(B

Full Text available with Trip Pro

2008 Journal of Antimicrobial Chemotherapy

182. Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms

of treatment that lasted 12 days. Patients who did not respond at the end of this period received a rescue antibiotic. In particular, linezolid was used as rescue therapy for patients who failed first-cycle teicoplanin, while quinupristin or dalfopristin was given to those who failed first-cycle linezolid. The time horizon of the analysis was 28 days. Measure of benefits used in the economic analysis The summary benefit measure was the therapeutic success (proportion of patients successfully cured

2005 NHS Economic Evaluation Database.

183. Cubicin - daptomycin

. The antibacterial activity of daptomycin requires the presence of free calcium. The exact mechanism of action of daptomycin remains to be determined. Due to its different mechanism of action, the antibacterial activity of daptomycin is not affected by mechanisms that confer specific resistance to beta-lactam agents (including methicillin), glycopeptides (such as vancomycin), quinupristin/dalfopristin, linezolid or other agents potentially useful against Gram-positive bacterial species. In both in vitro

2006 European Medicines Agency - EPARs

184. Validation of VITEK 2 Version 4.01 Software for Detection, Identification, and Classification of Glycopeptide-Resistant Enterococci (PubMed)

strains was misclassified as the vanB type, and one glycopeptide-susceptible E. facium wild type was misclassified as the vanA type. The overall essential agreements for antimicrobial susceptibility testing results were 94.2% for vancomycin, 95.9% for teicoplanin, 100% for quinupristin-dalfopristin and moxifloxacin, and 97.5% for linezolid. The rates of minor errors were 9% for teicoplanin and 5% for the other antibiotic agents. The identification and susceptibility data were produced within 4 h to 6

Full Text available with Trip Pro

2006 Journal of clinical microbiology

185. Clonal Diversity among Streptogramin A-Resistant Staphylococcus aureus Isolates Collected in French Hospitals (PubMed)

apparent size in 26 (42%) of the tested clinical isolates from 18 unrelated SmaI genotypes. The possible dissemination of some of the multiple clones characterized in the present study with an expected increased selective pressure of streptogramins following the recent licensing of Synercid (quinupristin-dalfopristin) must be carefully monitored.

Full Text available with Trip Pro

2003 Journal of clinical microbiology

186. Multiple-Antibiotic Resistance of Enterococcus spp. Isolated from Commercial Poultry Production Environments (PubMed)

% of the E. faecium isolates were resistant to the streptogramin quinupristin-dalfopristin, while high-level gentamicin resistance was observed only among the E. faecalis population, of which 7% of the isolates were resistant. The primary observations are that enterococci can be frequently isolated from the poultry production environment and can be multiresistant to antimicrobials used in human medicine. The high frequency with which resistant enterococci are isolated from this environment suggests

Full Text available with Trip Pro

2004 Applied and environmental microbiology

187. Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

PRIOR CONCURRENT THERAPY: See Disease Characteristics No concurrent class IA (e.g., quinidine or procainamide) or class III (e.g., amiodarone or sotalol) antiarrhythmics No concurrent intravenous antibiotics for pre-enrollment infections except vancomycin, linezolid, dalfopristin, or quinupristin (Synercid®) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact

2006 Clinical Trials

188. Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients

Bacterial Infections Gram-Positive Bacterial Infections Quinupristin-dalfopristin Anti-Bacterial Agents Anti-Infective Agents Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

2005 Clinical Trials

189. Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters

(nontunneled) temporary central venous catheter Males and females of at least 13 years of age A negative urine or serum pregnancy test at baseline Exclusion Criteria: Insertion of, or requirement for, any study catheter impregnated/bonded with an antimicrobial substance High probability of death within 14 days of enrollment as assessed by the investigator Prior treatment with vancomycin (intravenous administration only), daptomycin, linezolid, or quinupristin/dalfopristin, within 48 hours of first study

2005 Clinical Trials

190. Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma

Sulfadimidine Sulfinpyrazone Troglitazone Rifapentine Modafinil Amiodarone Anastrozole Clotrimazole Cyclosporine Danazol Delavirdine Diethyldithiocarbamate Diltiazem Dirithromycin Disulfiram Entacapone (high dose) Ethinyl estradiol Fluoxetine Fluvoxamine Gestodene Indinavir Isoniazid Metronidazole Mibefradil Miconazole Nefazodone Oxiconazole Paroxetine Propoxyphene Roxithromycin Quinidine Quinine Quinupristin and dalfopristin Ranitidine Ritonavir Saquinavir Sertindole Sertraline Troleandomycin Valproic acid

2003 Clinical Trials

191. Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria

; or bloodstream infection (including catheter-related). Pathogen resistant to, or patient intolerant of: beta-lactams, vancomycin, quinupristin/dalfopristin, or linezolid. Unable to receive any other standard commercially available antibacterial therapy for the infection. Main Exclusion Criteria: Creatinine clearance less than 40 mL/min** Hemodialysis or peritoneal dialysis Admitted to the hospital for drug overdose or other conditions associated with rhabdomyolysis, or is expected to require repeated

2003 Clinical Trials

192. Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid. (PubMed)

Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid. A 4 1/2-month-old, 26-week premature infant with multiple complications of prematurity required a central venous catheter for venous access and antibiotic treatment of bacterial nosocomial infections. He developed tricuspid valve endocarditis with vegetation caused by Enterococcus faecium resistant to ampicillin, vancomycin and quinupristin-dalfopristin but susceptible to linezolid

2003 Pediatric Infectious Dsease Journal

193. Mechanisms of action of newer antibiotics for Gram-positive pathogens. (PubMed)

combination quinupristin/dalfopristin (Synercid), the oxazolidinone linezolid, and the lipopeptide daptomycin. This review discusses the mechanisms of antibiotic action against Gram-positive pathogens, and resistance counter-mechanisms developed by Gram-positive bacteria, with emphasis on the newer agents.

2005 Lancet infectious diseases

194. Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619. (PubMed)

, including vancomycin, teicoplanin, arbekacin, linezolid and quinupristin/dalfopristin.MICs were determined by the agar dilution method using healthcare-associated MRS (S. aureus including strains with reduced susceptibility to vancomycin, 103; coagulase-negative staphylococci, 87) and community-associated MRS (S. aureus including non-multiresistant oxacillin-resistant strains, 37; coagulase-negative staphylococci, 92). The quinolone resistance-determining regions of gyrA, gyrB, grlA and grlB genes from

Full Text available with Trip Pro

2007 Journal of Antimicrobial Chemotherapy

195. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. (PubMed)

for invasive MRSA infections include linezolid, daptomycin, tigecycline, and quinupristin/dalfopristin. Additionally, a number of new anti-MRSA compounds are in development, including novel glycopeptides (dalbavancin, telavancin, and oritavancin), ceftobiprole, and iclaprim. The present article will review clinical issues surrounding the newly marketed and investigational agents with activity against MRSA.

Full Text available with Trip Pro

2007 Clinical Infectious Diseases

196. Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. (PubMed)

Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Among 203 strains of Staphylococcus aureus, the MICs of CG400549 were 0.06 to 1.0 microg/ml, with MIC(50) and MIC(90) values of 0.25 microg/ml each. All strains were susceptible to linezolid and quinupristin-dalfopristin (MICs, 0.25 to 2.0 microg/ml). The daptomycin MICs were 0.25 to 2.0 microg/ml for methicillin-susceptible and 0.25 to 4.0 microg/ml against methicillin-resistant

Full Text available with Trip Pro

2007 Antimicrobial Agents and Chemotherapy

197. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. (PubMed)

In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. To compare pharmacodynamic indices and minimal inhibitory concentrations for vancomycin, gatifloxacin, moxifloxacin, linezolid, and combined quinupristin and dalfopristin for historic and current human coagulase-negative staphylococcus (CoNS) endophthalmitis isolates.Experimental study.Fifty-nine CoNS endophthalmitis isolates retrieved from patients at the Bascom (...) divided by the concentration of the antibiotic required to inhibit a specified percentage of microbiologic isolates.Pharmacodynamic indices for new and conventional antibiotics.General in vitro susceptibility patterns in descending order were vancomycin (100%), linezolid (100%), quinupristin and dalfopristin (98%), moxifloxacin (48%), and gatifloxacin (47%). The corresponding MIC50 and MIC90 values were vancomycin, 2 microg/ml and 3 microg/ml, respectively; linezolid, 1 microg/ml and 4 microg/ml

2007 Ophthalmology

198. Endophthalmitis caused by enterococcus faecalis: antibiotic selection and treatment outcomes. (PubMed)

concentration >500 mg/l) in 5 of 29 eyes (17.2%), cefazolin in 7 of 8 eyes (87.5%), and quinupristin and dalfopristin in 29 of 29 eyes (100.0%). Preinfection baseline visual acuities ranged from 20/30 to hand motions. Visual acuities on presentation with endophthalmitis ranged from 2/200 to no light perception. Final visual acuity was better than or equal to 20/50 in two cases (6.9%), 20/60 to 20/400 in three cases (10.3%), 5/200 to hand motions in 10 cases (34.5%), and light perception to no light

2003 Ophthalmology

199. Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. (PubMed)

isolates were studied by the double disc test and PCR.In all, 16.8% of the isolates were non-susceptible (MIC > or =0.25 mg/L) to penicillin, but none showed high-level resistance (MIC > or =4 mg/L). Resistance to erythromycin, tetracycline, quinupristin/dalfopristin, levofloxacin and moxifloxacin was found in 22.4, 27.3, 13.0, 1.9 and 1.9% of the isolates, respectively. Combined resistance to erythromycin and tetracycline was found in 13.0% of the isolates. Erythromycin-resistant isolates were

Full Text available with Trip Pro

2003 Journal of Antimicrobial Chemotherapy

200. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. (PubMed)

streptogramin quinupristin/dalfopristin; DNA nanobinders GS2-10547 and GS02-104; peptide deformylase inhibitors NVP-PDF713 and GS02-12; tetracycline derivative tigecycline; the antifolate iclaprim; mupirocin and fusidic acid were all active in vitro but bacteriostatic.

Full Text available with Trip Pro

2003 Journal of Antimicrobial Chemotherapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>